Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells

(2010) L Eadie et al.   LEUKEMIA

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

(2009) Michele Baccarani et al.   JOURNAL OF CLINICAL ONCOLOGY

Chronic Myeloid Leukemia: Reversing the Chronic Phase

(2009) John M. Goldman   JOURNAL OF CLINICAL ONCOLOGY

Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy

(2009) D K Hiwase et al.   LEUKEMIA

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history

(2009) E Jabbour et al.   LEUKEMIA

Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

(2009) F J Giles et al.   LEUKEMIA

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications

(2008) D. K. Hiwase et al.   CLINICAL CANCER RESEARCH